Evidence map›Paper›PMID 31252521›Full record

ArticleMolecules (Basel, Switzerland)2019

Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group.

Stephan Mokesch, Daniela Schwarz, Michaela Hejl, Matthias H M Klose, Alexander Roller, Michael A Jakupec, Wolfgang Kandioller, Bernhard K Keppler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Stephan MokeschInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria.
Daniela SchwarzInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria.
Michaela HejlInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria.
Matthias H M KloseInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria.ORCID 0000-0002-7601-8333
Alexander RollerInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria.
Michael A JakupecInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria.ORCID 0000-0001-7945-1426
Wolfgang KandiollerInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria. wolfgang.kandioller@univie.ac.at.ORCID 0000-0002-5630-712X
Bernhard K KepplerInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria.
University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fine-tuning of the properties of a recently reported 1,3-indandione-based organoruthenium complex is attempted to optimize the stability under physiological conditions. Previous work has shown its capacity of inhibiting topoisomerase IIα; however, fast aquation leads to undesired reactions and ligand cleavage in the blood stream before the tumor tissue is reached. Exchange of the chlorido ligand for six different

Indexed as

Cell Line, TumorCoordination ComplexesCymenesDrug Screening Assays, AntitumorHumansInhibitory Concentration 50Molecular StructureRutheniumCoordination ComplexesCymenesRutheniumanticancer drugshalf-sandwich complexesleaving group variationruthenium(II)–arene complexes

Identifiers

PMID31252521
PMCPMC6651387
OpenAlexW2955012145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.